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Objectives. The aim of this study was to investigate the HLA-G serum levels in Primary Antiphospholipid Syndrome (PAPS)
patients, its impact on clinical and laboratory ﬁndings, and heparin treatment. Methods. Forty-four PAPS patients were age and
gender matched with 43 controls. HLA-G serum levels were measured using an enzyme-linked immunosorbent assay (ELISA).
Results. An increase in soluble HLA-G levels was found in patients compared to controls (3.35 (0–22.9) versus 1.1 (0–14),
P = 0.017). There were no signiﬁcant diﬀerences in HLA-G levels between patients with and without obstetric events, arterial
thrombosis, venous thrombosis, or stroke. Sixty-six percent of patients were being treated with heparin. Interestingly, patients
treated with heparin had higher HLA-G levels than ones who were not treated with this medication (5 (0–22.9) versus 1.8 (0–
16)ng/mL, P = 0.038). Furthermore, patients on heparin who experienced obstetric events had a trend to increased HLA-G levels
compared to patients who were not on heparin and did not have obstetric events (5.8 (0–22.9) versus 2 (0–15.2)ng/mL, P = 0.05).
Conclusion. This is the ﬁrst study to demonstrate that serum HLA-G levels are increased in APS patients. We also demonstrated
that heparin increases HLA-G levels and may increase tolerance towards autoantigens.
1.Introduction
Human leukocyte antigen- (HLA-) G is a nonclassical HLA
class Ib molecule from the major histocompatibility com-
plex. It was originally discovered in the context of protecting
a fetus from the mother’s immune system [1]. Indeed, HLA-
G seems to be involved in the induction and maintenance
of tolerance between the mother’s immune system and the
semiallogeneic fetus at the fetal-placental interface; it also
seems to play an important role in embryo implantation
[2]. Beyond its role in fetal-maternal tolerance, HLA-G
exerts tolerogenic functions in transplant acceptance and
in tumoral and viral immune escape [1]. HLA-G antigens
can aﬀect the cytotoxicity of natural killer and CD8+ T
cells, CD4+ T-lymphocyte functions, and dendritic cell
maturation [3].
Recent studies have demonstrated the altered expression
ofHLA-Ginautoimmunediseases,suchasmultiplesclerosis,
rheumatoid arthritis, and systemic lupus erythematosus
(SLE),suggestingaroleforthismoleculeinthepathophysio-
logy of autoimmune diseases [4–7]. Antiphospholipid syn-
drome(APS)isanautoimmunediseasefrequentlyassociated
with obstetric complications including fetal loss, recurrent
spontaneous abortions, and placental insuﬃciency. Conse-
quently, alterations in the HLA-G system might be a possible
mechanism involved in the etiology of this autoimmune2 Clinical and Developmental Immunology
disorder. However, there is no other study that evaluated
HLA-G levels in APS patients. This report represents the ﬁrst
investigation of the role of HLA-G in APS.
Thepresentstudywasthereforeundertakentodetermine
the serum HLA-G levels in patients with PAPS and to under-
stand the possible associations between HLA-G levels and
clinical and laboratory ﬁndings in PAPS.
2. Methods
2.1. Patients. This is a cross-sectional study that included 44
patients with PAPS, according to Sapporo criteria [8], and 43
age- and race-matched healthy subjects who served as con-
trols.AllpatientswerefollowedattheAntiphospholipidSyn-
drome Outpatient Clinic within the Division of Rheumatol-
ogy at the Hospital das Cl´ ınicas da Faculdade de Medicina da
Universidade de S˜ ao Paulo.
Patients who had secondary causes of APS, such as SLE,
rheumatoid arthritis (RA), or vasculitis, were excluded from
this study.
All subjects provided informed consent, and the study
wasapprovedbytheEthicsCommitteeoftheUniversityHos-
pital.
2.2. Data Collection. Demographic data for patients and
controls were obtained through interviews and physical
examinations. Variables collected included age in years, gen-
der,race,andweight.Clinicalandtherapeuticdata,including
disease duration, thrombotic and obstetric manifestations,
and medication history including administration of war-
farin, heparin, aspirin, anticonvulsants, and antimalarials,
were obtained from the medical records and interviews.
2.3. Measurement of sHLA-G. Capture enzyme-linked im-
munosorbentassay(ELISA)wasusedtomeasureHLA-Glev-
els.Brieﬂy,96-wellmicroplates(Nunc-C8MaxiSorpBreakA-
part Immunomodule, Roskilde, Denmark) were coated for
72h with 100µL/well of monoclonal antibody MEM-G/9
(MCA2004-Serotec, Raleigh-NC, USA) in 10µg/mL BBS
(pH 8.4) and incubated at 4◦C. After three washes with
PBS, 200µL of a solution containing 5% bovine serum and
10% sucrose in PBS was added to the wells, and the plates
were incubated for 12h at 4◦C. Before use, this solution was
aspirated, and plates were incubated for 2h at 37◦C. FiftyµL
of calibration solution (diluted to 0, 3.125, 6.25, 12.5, and
25.0ng/mL) from JEG-3 cells (human placental choriocar-
cinoma), or sera from patients and controls (undiluted),
was added in duplicate and followed by an incubation for
2h at room temperature (RT). After three washings with
PBS, 50µL of a peroxidase-conjugated IgG fraction of rabbit
anti-beta-2-microglobulin (Rockland Inc., Gilbertsville, PA,
US), diluted 1:500 in PBS with 10% normal rabbit serum,
was added and incubated for 1h at RT. The reaction was
developed with 100µL of TMB, and after 30min the reaction
was stopped with H2SO4 1N .P l a t e sw e r er e a da ta no p t i c a l
density (OD) of 450nm (EL Universal Microplate Reader,
BioTek Instruments Inc., Winooski, VT, USA). HLA-G levels
were calculated using a standard curve and results were
expressed inng/mL [9, 10]. The intra-assay CV was 3.2 to
6.9% and the interassay 7.7 to 13.9%.
2.4. Antiphospholipid Antibodies. IgG and IgM anticardi-
olipin antibodies (aCL) were tested at least twice, with an in-
terval of 12 weeks between measurements, using an ELISA as
previously described [11]. According to the manufacturer’s
recommendations,onlytitersofaCL>20U/mLwereconsid-
ered positive. Lupus anticoagulant was measured according
to international guidelines using activated partial thrombo-
plastin time (APTT, Diagnostica Stago, France) and diluted
Russell’s viper venom time (dRVVT, Trinity Biotech, Wick-
low, Ireland) [12].
2.5.StatisticalAnalysis. Dataarereportedasamedian(mini-
mum-maximum) for HLA-G serum levels, mean (± stan-
dard deviation), or a percent. Variables were compared be-
tween patients and controls using Student’s t-test or the Chi-
square test. P values < 0.05 were considered signiﬁcant.
3. Results
Patients and controls were similar in terms of age (42.5 ±
12.0v e r s u s3 9 .8 ± 11.2y e a r s ,P = 0.29, t-test), frequency of
femalegender(86.4versus78.9%,P = 0.47,Chi-squaretest),
and Caucasian race (90.9 versus 84.2%, P = 0.42, Chi-square
test). Mean disease duration was 97.9 ±70.3 months.
Arterial thrombosis was observed in 59.1% of patients,
venous thrombosis in 59.1%, obstetric events in 38.6%,
thrombocytopenia in 18.2%, livedo reticularis in 34.1%,
stroke in 43.2%, Sneddon’s syndrome in 24.5%, pulmonary
thromboembolism in 27.3%, deep venous thrombosis in
54.5%, and angina in 9.1%. In patients with PAPS, 38.6%
reported prior smoking history and 11.4% were current
smokers (Table 1). Lupus anticoagulant was positive in
60.5% of patients, IgG anticardiolipin in 36.8%, and IgM
anticardiolipin antibodies in 10.5%. Sixty-six percent of
patients were being treated with heparin, and 40.9% were
being treated with chloroquine diphosphate.
Notably, signiﬁcantly increased levels of soluble HLA-G
were noted in PAPS patients compared to controls (3.35 (0–
22.9) versus 1.1 (0–14), P = 0.017, Mann-Whitney test)
(Table 1, Figure 1). Serum HLA-G levels were similar in
patients with and without obstetric events, arterial thrombo-
sis, venous events, and stroke (P>0.05) (Mann-Whitney
test) (Table 2).
Interestingly, patients taking heparin had higher HLA-
G levels than subjects who were not using this medication
(5 (0–22.9) versus 1.8 (0–16)ng/mL, P = 0.038, Mann-
Whitney test) (Figure 1). Furthermore, patients taking hep-
arin who had obstetric events (n = 1 3 )h a dat r e n dt oi n -
creased levels of HLA-G compared to other patients (n = 25)
(5.8 (0–22.9) versus 2 (0–15.2)ng/mL, P = 0.05, Mann-
Whitney test).
Patients taking heparin who experienced arterial throm-
bosis (n = 16) had similar levels of HLA-G compared
to the other patients (n = 28) (4.55 (0–15.2) versus
3.2 (0–22.9)ng/mL, P = 0.557, Mann-Whitney test), and
patients taking heparin who experienced venous thrombosisClinical and Developmental Immunology 3
Table 1: Demographic, anthropometric, clinical, and laboratory features of the 44 PAPS patients and 43 healthy controls that provided
samples for the measurement of HLA-G levels.
PAPS
n = 44
Controls
n = 43 P
Age, years 42.47 (12.0) 39.83 (11.2) 0.29
White race, % 90.9 84.2 0.42
Arterial events, % 59.1 NA —
Venous events, % 59.1 NA —
Obstetric events, % 38.6 NA —
Thrombocytopenia, % 18.2 NA —
Livedo reticularis, % 34.1 NA
Stroke, % 43.2 NA —
Sneddon’s syndrome, % 24.5 NA —
Pulmonary thromboembolism, % 27.3 NA —
Deep venous thrombosis, % 54.5 NA —
Angina, % 9.1 NA
Disease duration, months 97.9 (70.3) NA —
Previous history of smoking, % 38.6 NA —
Current smoking, % 11.4 NA —
Heparin use, % 66 NA —
Current chloroquine use, % 40.9 NA —
HLA-G,ng/mL# 3.35 (0–22.9) 1.1 (0–14) 0.017
NA: not applicable.
Data expressed as a mean (standard deviation), #median (minimum-maximum), or a percentage.
Table 2: Comparison of HLA-G levels between primary antiphospholipid syndrome patients (PAPS) with and without clinical events.
HLA-G levels in PAPS with clinical events HLA-G levels in PAPS without clinical events P
Obstetric event 5.4 (0–22.9) 2.0 (0–15.2) 0.206
Arterial event 2.5 (0–15.2) 4.8 (0–22.9) 0.304
Venous event 2.9 (0–22.9) 4.15 (0–15.2) 0.574
Stroke 2.4 (0–16) 5 (0–22.9) 0.18
Data expressed as a median (minimum-maximum) inng/mL.
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Figure 1: HLA-G serum levels in 44 PAPS patients and 43 healthy
controls, and in PAPS patients with and without heparin.
(n = 18) had comparable levels of HLA-G compared to the
others (n = 26) (3.6 (0–22.9) versus 3.35 (0–15.9)ng/mL,
P = 0.990, Mann-Whitney test).
4. Discussion
This is the ﬁrst study to demonstrate higher levels of HLA-G
in PAPS patients compared to healthy subjects.
One advantage of this study was the inclusion of
exclusively primary APS patients because it is clear that SLE
can alter HLA-G levels [6, 7] .I n d e e d ,p r e v i o u ss t u d i e so f
HLA-G in SLE have presented conﬂicting results [6, 7, 13].
Lower plasma levels of soluble HLA-G were more frequent
in patients with SLE [6]. Wu et al. [13] demonstrated a signi-
ﬁcantincreaseintheexpressionofsolubleHLA-Ginpatients
with SLE; high levels of soluble HLA-G were also associated
with more active disease and more neurologic involvement.
It is possible that enhanced expression of soluble HLA-G in4 Clinical and Developmental Immunology
SLE contributes to a mechanism that restores tolerance tow-
ards autoantigens and counteracts inﬂammation. However,
the participation of this molecule in the pathologic process
of SLE has not been excluded. Thus, environmental and/or
ethnicity-speciﬁc factors may be contributing to such con-
ﬂicting results.
RecentstudieshavedemonstratedthatHLA-Gisinduced
with the development of inﬂammatory pathologies such
as myositic lesions, psoriatic lesions on skin, and multiple
sclerosis [4, 14, 15]. Furthermore, HLA-G expression on the
surface of epithelial intestinal cells seems to play a role in
the suppression of proinﬂammatory cytokines in ulcerative
colitis [16]. It has been suggested that HLA-G expres-
sion plays a role in a possible mechanism of tissue protection
against autoimmune inﬂammatory responses, therefore act-
ing as a mechanism of immune surveillance [17, 18]. In this
regard, a combination of genes, instead of a single gene, pre-
disposes one to an immunologic disorder that leads to defec-
tive mechanisms of immunological tolerance, allowing anti-
bodyproductionagainstautoantigens,immunecomplexfor-
mation, and deposition [19].
Our study provided an opportunity to assess the possible
connections between PAPS and HLA-G levels. While we de-
monstratedthatHLA-GlevelsareincreasedinPAPSpatients,
we did not observe a diﬀerence in the HLA-G levels in
patients who had clinical manifestations of PAPS, including
obstetric events.
Recent evidence suggests that HLA-G may be involved in
thesuppressionofimmuneresponsesincluding inhibition of
the proliferation of CD4+ T cells, induction of CD4+ T-cell
anergy, and diﬀerentiation of CD4+ T cells into suppressive
cells [20]. A similar process was suggested to explain the
higher soluble HLA-G expression in correlation with RA dis-
ease activity [21].
One possible explanation is that heparin could increase
HLA-G expression on target tissues. In fact, Baczyk et al.
demonstrated that heparin plus ﬁbroblast growth factor 4
(FGF4) induced an increase of HLA-G expression with more
invasiveness of trophoblast tissue [22].
The most interesting ﬁnding in this study was that
patientstakingheparinhadhigherHLA-Gthanpatientswho
were not treated with this medication. Furthermore, patients
on heparin who experienced obstetric events had a trend to
increased levels of HLA-G compared to patients not taking
heparin who did not have obstetric events. These ﬁndings
suggest a possible enhanced expression of soluble HLA-G in
PAPS as part of a mechanism to restore the tolerance process
towards autoantigens; it also demonstrates that hepar-
in increases HLA-G levels and may increase this immuno-
logic aberrancy. Kovats et al. [2] demonstrated that HLA-G
is expressed in cytotrophoblasts. They identiﬁed a molecule
andagenethatcouldbeinvolvedinplacental-maternalinter-
action and could be studied quantitatively and qualitatively
in connection with certain types of unexplained infertility
and spontaneous abortion [23].
In summary, this study demonstrated higher levels of
HLA-G in PAPS, particularly in patients with obstetric
events. We also demonstrated that heparin increases HLA-G
levels and may increase tolerance towards autoantigens.
5.Rheumatology Key Messages
(i) Serum HLA-G levels are increased in antiphospho-
lipid syndrome patients in comparison to healthy
controls.
(ii) Heparin treatment increases HLA-G levels in
antiphospholipid syndrome patients with obstetric
events.
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